Renovaro Biosciences CEO Dr Mark Dybul joined Steve Darling from Proactive to share news about the significant progress the company is poised to make following the signing of a definitive agreement to merge with GEDiCube, a UK-based medical AI company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. GEDiCube is set to rebrand as Renovaro.AI, and together, the entities are looking to hasten diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases.
Dybul highlighted to Proactive that while Renovaro is currently concentrated on pancreatic cancer research, plans are afoot to extend their focus to include other solid tumors that are typically associated with a short life expectancy. These will be part of the first human Phase I/IIa studies anticipated to commence by mid-2024. He noted the potential of GEDi Cube’s AI technology to refine the focus of upcoming human trials on those cancers that are most amenable to treatment. Furthermore, the technology is expected to enrich the database of crucial markers for early diagnosis and tracking disease progression, thereby fostering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of completely new therapeutic options.